Scientists are still divided over the broad use of COVID-19 vaccine boosters among those without underlying problems
(Corrects to Minnesota from Michigan in paragraph 12)
By Manas Mishra and Michael Erman
Aug 13 (Reuters) - The U.S. Food and Drug Administration has authorized a third dose of COVID-19 vaccines by Pfizer Inc -BioNTech and Moderna Inc for people with compromised immune systems.
The amended https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised emergency use authorization on Thursday paves the way for people who have had an organ transplant, or those with a similar level of weakened immune system, to get an extra dose of the same shot they have initially received. Mixing of mRNA vaccines is permitted for the third shot if their original vaccine is not available.
An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) on Friday voted to recommend the additional doses, an important step before the policy is implemented.
Patients will not need a prescription or the sign off of a health care provider in order to prove they are immunocompromised and receive the additional dose, according to CDC officials.
"It will be a patient's attestation, and there will be no requirement for proof or prescription or a recommendation from an individual's health care provider," CDC official Dr. Amanda Cohn said, speaking before the Advisory Committee on Immunization Practices vote.
The vulnerable group makes up less than 3% of U.S. adults, Rochelle Walensky, director of the CDC, had said before the authorization.
"After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines," Janet Woodcock, U.S. FDA's acting commissioner, said in a tweet https://twitter.com/DrWoodcockFDA/status/1426019820445868033 on Thursday.
Woodcock said that others who are fully vaccinated do not need an additional vaccine dose right now.
The FDA's decision does not apply to people who received the one-dose Johnson & Johnson vaccine, the CDC said, because there is not enough data to support additional doses yet.
"We think that at least this is a solution for the very large majority of immunocompromised individuals, and we believe that we'll probably have a solution for the remainder in the not-too-distant future," FDA official Peter Marks told the CDC panel.
The FDA and the CDC are working to ensure that immunocompromised recipients of the J&J vaccine have optimal protection, the CDC said.
Dr. David Boulware, an infectious disease doctor at the University of Minnesota, backed the FDA decision, noting that many of the people who have been hospitalized after vaccination are immunocompromised.
Boulware said that the plan to let patients attest to their own status may lead to more people receiving the shots than intended.
"If it is left up to the honor system, I think many Americans will suddenly wake up and find themselves immunocompromised enough to get a 3rd dose," he said in an email.
BOOSTERS FOR YOUNG, HEALTHY
Scientists are still divided over the broad use of COVID-19 vaccine boosters among those without underlying problems as benefits of the boosters remain undetermined.
Pfizer has previously said the efficacy of the vaccine it developed with partner BioNTech drops over time.
Moderna has also said it sees the eventual need for booster doses, especially since the Delta variant has caused "breakthrough" infections in fully vaccinated people.
Reports of infections among vaccinated people and concerns about diminishing protection have galvanized wealthy nations to distribute booster shots, even as many countries struggle to access first vaccine doses.
The World Health Organization last week called for a moratorium on COVID-19 vaccine booster shots until at least the end of September.
Still, Americans have already started getting additional shots, even before the FDA has authorized them. According to the CDC, more than 1.2 million people have already received one or more additional doses of a COVID-19 vaccine already.
Wall Street analysts expect the authorization of a booster dose for a broad population to bolster profits of COVID-19 vaccine makers.
Shares of Pfizer, Moderna and U.S.-listed shares of BioNTech rose between 1% and 2% in early trading.
(Reporting by Manas Mishra in Bengaluru; Additional reporting by Bhargav Acharya; Editing by Shounak Dasgupta, Shinjini Ganguli, Aurora Ellis and Nick Zieminski)